What America’s dead can teach us about America’s living.
Happy Monday. Let’s talk about death.
I had the privilege of chatting with Bob Anderson on Friday. Anderson is the director of the Mortality Statistics Branch at the CDC’s National Center for Health Statistics, the group responsible for counting America’s dead.
The last time we had spoken was in 2009, and Anderson and his crew had just finished compiling the official tally of 2006’s fatalities. It had taken a full 30 months to gather records from all 50 states, the District of Columbia, the five island territories from Puerto Rico to Guam, and New York City—which, for odd reasons, maintained its own vital records—then plug the many holes (recoding the cause of death for some states entirely), clear up discrepancies, sort, cross-reference, tabulate the numbers in hundreds of ways, and summarize the lot into a single, cohesive report.
Back then, much of the processing of mortality data at the state level, almost unthinkably, was being done by hand. Now, with the exception of eleven of the 57 reporting jurisdictions above—the five territories and six holdout states (West Virginia, North Carolina, Mississippi, Tennessee, Rhode Island, and Connecticut)—the process has become mostly electronic. Currently, 47% of death records are sent to Anderson’s team within 10 days of the person’s passing. The entire national tally now takes about eleven months to complete.
It’s no mean feat.
There are roughly 8,000 ways to die—which is to say there are about 8,000 categories in the 10th and latest edition of the International Classification of Diseases. And Anderson and his crew of statisticians, analysts, and nosologists on the fifth floor of a seven-floor office building in Hyattsville, Maryland, will soon publish their report detailing precisely which of those ways took the lives of 2,712,630 U.S. residents in 2015. (An interim data brief was released last December.)
The answers are not always as black-and-white as the death certificates they’re written on. The cause, in each case, is determined by an attending physician or coroner or medical examiner, who in turn often relies on medical histories provided by the families—or, say in the case of a car accident or gunshot wound, on the sheer apparentness of injury. Contrary to the impression left by television crime dramas, formal autopsies are seldom done. (Fewer than one in ten bodies these days are hauled to the lab and cut open by a medical examiner.) Nor, in the vast majority of cases, are so-called pronouncing doctors trained in forensic pathology. Mistakes are as inevitable as they are expected.
On the whole, though, they tend toward the minor—conflating the “immediate” and “underlying” causes of death, for instance, or confusing two related forms of disease. Such flaws notwithstanding, death certificates are the best documentary evidence there are when it comes to studying the health and well being of any population. It is almost impossible, for instance, to understand disease burden or do major epidemiological studies without them. No public or private record offers a more definitive account of the extent of illness and injury in the country. To health policy officials, certainly, no nationwide set of data is anywhere near as essential.
Once a physician has signed off on the cause of death, it’s the task of a funeral director to supply the rest of the information on the legal certificate—the who, when, where, how old, and more—and send the form to the local or state registrar. State workers then send a record of this assessment to Anderson’s team at the NCHS who code it with one of those 8,000 or so potential causes in the ICD—which over a century of use and revision has become the globe’s single compendium to mortality. (Death, ironically, has managed to unite the world where the commonality of life cannot: ICD’s expansive alphanumeric code is perhaps the only language shared by nearly every government on the planet.)
These are the blunt, industrial-scale mechanics of counting death in the U.S. The marvel is in how such painting-by-numbers can yield, year after year, an image of near-animate detail: a national portrait of death—and to some extent, its inverse, a portrait of life.
So what do we see right now in that self-portrait of America? A face that’s a little more weathered than it was in the previous year, and perhaps a fraction less vital, too. From 2014 to 2015, life expectancy for the U.S. population actually dipped one-tenth of a year, from 78.9 years to 78.8—its first drop in more than two decades. The age-adjusted death rate in America rose for eight of the 10 leading causes of mortality and increased 1.2% overall.
Indeed, for one of those causes—Alzheimer’s disease—the rate didn’t merely creep upward, it leaped, shooting up 15.7% year over year. This, after climbing 55% between 1999 and 2014, according to a CDC report. Those numbers are a shout of warning, or ought to be.
“The increasing rates of Alzheimer’s deaths are not only problematic because of their obvious direct health effects on persons with Alzheimer’s,” says the CDC, plainly. “The debilitating nature of Alzheimer’s” translates into mammoth financial costs that are “borne by patients and their families, and by states and counties that operate publicly funded long-term care facilities.”
More than two thirds of the $259 billion cost of caring for those with Alzheimer’s and other forms of dementia will be paid by Medicare, Medicaid, and other public sources. But “most care provided to older adults with Alzheimer’s who do not live in long-term care facilities is provided by family members or other unpaid caregivers,” the CDC points out. And the agency calculates that this care amounted to 18.2 billion hours of unpaid assistance last year. (Yes, that’s billion with a “b.”)
Anderson has seen this and other American storylines unfold in real-time in the data of death: the stark and scary rise in opioid-related fatalities, the happy decline in infant mortality, the still-unexplained rise in suicides in the country.
A soft-spoken fellow from Sugarland, Texas, Anderson fell into his role by accident. After changing his undergraduate major four times, he pursued a graduate degree in demography at Penn State—but even then he was more interested in studying statistics about marriage and family than death. But “the job market was poor for demographers,” he says, and an ad for a position at the mortality branch just happened to land in his lap. And maybe, just maybe, the job was in his blood anyway: “My grandfather was a funeral director, mortician, ambulance driver, and county coroner, in Madison County, Idaho,” he says.
When I ask him what he’s learned in 20 years of counting bodies, Anderson answers quickly: “Everybody dies,” he says.
Then he pauses for a moment and offers something else: “Death gives life perspective.”
That one stuck with me.
More news below.
|Clifton Leaf, Editor in Chief, FORTUNE|
Another liquid biopsy advance, this time from Grail. The quest to develop a simple blood test to detect cancer and avoid painful, pricey, and expensive tissue biopsies has been humming along in recent years (albeit with lingering concerns from some medical experts). Now, Grail, a spinoff of genomic sequencing firm Illumina, has presented its own promising preliminary results for liquid biopsy tech during the ongoing American Society of Clinical Oncology (ASCO) cancer conference in Chicago. Grail describes its own approach to the blood tests as “high intensity” because it scans blood samples for cancer-related mutations in more than 500 genes tens of thousands of times. “Basically, what they’re showing is that they can detect in blood the majority of the same mutations that they can detect in tissue of patients with advanced cancer,” as ASCO’s Dr. Richard Schilsky put it. (Fortune)
Novartis teams up with IBM Watson Health on breast cancer project. Swiss pharma giant Novartis and the ever deal-making IBM Watson Health are collaborating on a new project to use patient data and machine learning in order to suss out which treatments may be most effective for breast cancer patients. “Through this collaboration with IBM Watson Health, we will use real-world breast cancer data and cognitive computing to identify solutions that may help physicians better understand which therapy may be best for which patients or advise clinical practice guidelines,” said Novartis Oncology head Bruno Strigini in a statement. IBM Watson Health has struck similar partnerships on precision medicine and drug efficacy with a number of other partners. (Reuters)
All eyes are on the world’s biggest cancer conference. The annual ASCO cancer conference kicked off last Friday in Chicago and will be going strong through tomorrow. There’s already a whole host of data to sift through and emerging narratives about small biotechs butting heads with some of the world’s biggest drug makers when it comes to developing the next generation of cancer treatments (I’ll have more in-depth coverage ASCO coverage today and tomorrow). In the meantime, here are some of the highlights: Chinese biotech Nanjing Legend produced impressive early results in a new type of blood cancer treatment technique that re-engineers patients’ own immune cells to fight the disease; an experimental Pfizer cancer drug bested a rival from AstraZeneca, but Roche came out on top of the former company in a lung cancer trial of two different treatments; and Kite Pharma announced it will be launching a mid-stage trial of its experimental blood cancer therapy by the end of the year.
THE BIG PICTURE
M*A*S*H star Alan Alda’s new book explores how communication is key in science and medicine. Actor Alan Alda, perhaps best known for his role in the hit war dramedy M*A*S*H, has been invested in communications for years. And his latest book, “If I Understood You, Would I Have This Look on My Face?”, explores how better communication can help doctors, patients, scientists, and consumers alike. Alda told NBC News that his Center for Communicating Science has actually trained more than 8,000 scientists and medical professionals throughout the world on the best, most effective way to relay information—which could become increasingly important as scientific establishments are under attack. (NBC News)
Quickly reporting cancer complications boosts survival. A new study finds that promptly reporting potential cancer (and cancer treatment) side effect symptoms like nausea and fatigue through an online tool can boost cancer patients’ survival to an impressive degree. Just how much? According to the study, by nearly half a year. That may not sound like a lot, but it’s actually a bigger survival spike than that offered by many pricey new cancer drugs. (ABC News)
The Real Reason Trump Left the Paris Agreement, by Mark Mills
Google Is Going Ahead With Controversial Ad Blocking Plans for Chrome, by Mathew Ingram
Read Uber CEO’s Heart Wrenching Note About His Parents’ Fatal Boat Accident, by Polina Marinova
|Produced by Sy Mukherjee|
Find past coverage. Sign up for other Fortune newsletters.